ATHA vs. BTAI, CLNN, CUE, DTIL, DRRX, COEP, VTVT, ICCC, KPTI, and ZIVO
Should you be buying Athira Pharma stock or one of its competitors? The main competitors of Athira Pharma include BioXcel Therapeutics (BTAI), Clene (CLNN), Cue Biopharma (CUE), Precision BioSciences (DTIL), DURECT (DRRX), Coeptis Therapeutics (COEP), vTv Therapeutics (VTVT), ImmuCell (ICCC), Karyopharm Therapeutics (KPTI), and ZIVO Bioscience (ZIVO). These companies are all part of the "pharmaceutical products" industry.
Athira Pharma vs. Its Competitors
Athira Pharma (NASDAQ:ATHA) and BioXcel Therapeutics (NASDAQ:BTAI) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment and valuation.
Athira Pharma has a net margin of 0.00% compared to BioXcel Therapeutics' net margin of -5,869.82%. BioXcel Therapeutics' return on equity of 0.00% beat Athira Pharma's return on equity.
BioXcel Therapeutics has higher revenue and earnings than Athira Pharma. Athira Pharma is trading at a lower price-to-earnings ratio than BioXcel Therapeutics, indicating that it is currently the more affordable of the two stocks.
57.1% of Athira Pharma shares are owned by institutional investors. Comparatively, 30.7% of BioXcel Therapeutics shares are owned by institutional investors. 22.1% of Athira Pharma shares are owned by insiders. Comparatively, 21.2% of BioXcel Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Athira Pharma presently has a consensus price target of $4.00, indicating a potential upside of 3.36%. BioXcel Therapeutics has a consensus price target of $39.75, indicating a potential upside of 1,229.43%. Given BioXcel Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe BioXcel Therapeutics is more favorable than Athira Pharma.
In the previous week, BioXcel Therapeutics had 5 more articles in the media than Athira Pharma. MarketBeat recorded 9 mentions for BioXcel Therapeutics and 4 mentions for Athira Pharma. BioXcel Therapeutics' average media sentiment score of 0.33 beat Athira Pharma's score of -0.01 indicating that BioXcel Therapeutics is being referred to more favorably in the news media.
Athira Pharma has a beta of 3.01, suggesting that its share price is 201% more volatile than the S&P 500. Comparatively, BioXcel Therapeutics has a beta of 0.2, suggesting that its share price is 80% less volatile than the S&P 500.
Summary
BioXcel Therapeutics beats Athira Pharma on 11 of the 16 factors compared between the two stocks.
Get Athira Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for ATHA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ATHA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Athira Pharma Competitors List
Related Companies and Tools
This page (NASDAQ:ATHA) was last updated on 9/20/2025 by MarketBeat.com Staff
Free ATHA Stock Alerts